Who Truly Benefits From First-Line Intensification in EGFR-Mutant NSCLC?
{{output}}
Purpose of review: The treatment landscape for advanced non-small cell lung cancer (NSCLC) with common EGFR mutations has evolved significantly, with osimertinib established as the first-line standard. Two recent phase III trials... ...
